Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
NK Cell Innovation | Artiva Biotherapeutics pioneers NK cell therapies for autoimmune diseases, offering a potentially safer alternative to CAR-T treatments with lower manufacturing costs |
Financial Fortitude | With a strong cash position and runway through 2026, Artiva is well-positioned to advance its clinical trials and expand into multiple autoimmune indications |
Market Opportunity | Analyst price targets range from $18 to $23, reflecting optimism about Artiva's potential in the substantial autoimmune disease market |
Competitive Edge | Explore Artiva's scalable manufacturing process and low COGS, which could provide a significant advantage in the crowded immunology market |
Metrics to compare | ARTV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARTVPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.7x | −0.5x | −0.5x | |
PEG Ratio | −0.01 | 0.00 | 0.00 | |
Price/Book | 0.3x | 1.0x | 2.6x | |
Price / LTM Sales | - | 17.9x | 3.0x | |
Upside (Analyst Target) | - | 209.9% | 54.1% | |
Fair Value Upside | Unlock | 7.6% | 8.7% | Unlock |